Antipsychotic induced dopamine supersensitivity psychosis: A comprehensive review

Current Neuropharmacology

Volumn 15, Issue 1, 2017, Pages 174-183

  Yin, John ^a   Barr, Alasdair M ^a   Ramos Miguel, Alfredo ^a   Procyshyn, Ric M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antipsychotics; D2 receptors; Dopamine supersensitivity psychosis; Rebound psychosis; Relapse; Schizophrenia; Tolerance; Treatment resistance

Indexed keywords

ARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUINPIROLE; RGS PROTEIN;

ANIMAL BEHAVIOR; APOMORPHINE TEST; AVOIDANCE BEHAVIOR; BINDING AFFINITY; CONDITIONED AVOIDANCE RESPONSE TEST; DOPAMINE RELEASE; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; DRUG INDUCED PSYCHOSIS; DRUG RESPONSE; DRUG TOLERANCE; DRUG WITHDRAWAL; EXPERIMENTAL HYPERACTIVITY; HUMAN; META ANALYSIS (TOPIC); NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; RELAPSE; REVIEW; SCHIZOPHRENIA; SUPERSENSITIVITY; TARDIVE DYSKINESIA; TREATMENT OUTCOME; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PSYCHOTIC DISORDERS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE AGENTS; GENE EXPRESSION REGULATION; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2;

EID: 85011728929     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X14666160606093602     Document Type: Review

References (85)

1. Saha, S.; Chant, D.; Welham, J.; McGrath, J. A systematic review of the prevalence of schizophrenia. PLoS Med., 2005, 2(5), e141. [http://dx.doi.org/10.1371/journal.pmed.0020141] [PMID: 15916472]
2. Robinson, D.; Woerner, M.G.; Alvir, J.M.; Bilder, R.; Goldman, R.; Geisler, S.; Koreen, A.; Sheitman, B.; Chakos, M.; Mayerhoff, D.; Lieberman, J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry, 1999, 56(3), 241-247. [http://dx.doi.org/10.1001/archpsyc.56.3.241] [PMID: 10078501]
3. Emsley, R.; Chiliza, B.; Asmal, L.; Harvey, B.H. The nature of relapse in schizophrenia. BMC Psychiatry, 2013, 13, 50. [http://dx.doi.org/10.1186/1471-244X-13-50] [PMID: 23394123]
4. Lehman, A.; Lieberman, J.; Dixon, L.; McGlashan, T.; Miller, A.; Perkins, D.; Kreyenbuhl, J. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry, 2004, 161(2), 1-56. http://psychiatryonline.org/pb/assets/raw/sitewide/practice:guidelines/guidelines/schizophrenia.pdf
5. Clinical practice guidelines. Treatment of schizophrenia. Can. J. Psychiatry, 2005, 50(13)(Suppl. 1), 7S-57S. [PMID: 16529334]
6. Harrow, M.; Jobe, T.H.; Faull, R.N. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol. Med., 2014, 44(14), 3007-3016. [http://dx.doi.org/10.1017/S0033291714000610] [PMID: 25066792]
7. Wunderink, L.; Nieboer, R.M.; Wiersma, D.; Sytema, S.; Nienhuis, F.J. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry, 2013, 70(9), 913-920. [http://dx.doi.org/10.1001/jamapsychiatry.2013.19] [PMID: 23824214]
8. Harrow, M.; Grossman, L.S.; Jobe, T.H.; Herbener, E.S. Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophr. Bull., 2005, 31(3), 723-734. [http://dx.doi.org/10.1093/schbul/sbi026] [PMID: 16020553]
9. Samaha, A.N.; Seeman, P.; Stewart, J.; Rajabi, H.; Kapur, S. Breakthrough dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci., 2007, 27(11), 2979-2986. [http://dx.doi.org/10.1523/JNEUROSCI.5416-06.2007] [PMID: 17360921]
10. Seeman, P. Are dopamine D2 receptors out of control in psychosis? Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 46, 146-152. [http://dx.doi.org/10.1016/j.pnpbp.2013.07.006] [PMID: 23880595]
11. Iyo, M.; Tadokoro, S.; Kanahara, N.; Hashimoto, T.; Niitsu, T.; Watanabe, H.; Hashimoto, K. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J. Clin. Psychopharmacol., 2013, 33(3), 398-404. [http://dx.doi.org/10. 1097/JCP.0b013e31828ea95c] [PMID: 23609386]
12. Chouinard, G.; Jones, B.D. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am. J. Psychiatry, 1980, 137(1), 16-21. [http://dx.doi.org/10.1176/ajp.137.1.16] [PMID: 6101522]
13. Suzuki, T.; Kanahara, N.; Yamanaka, H.; Takase, M.; Kimura, H.; Watanabe, H.; Iyo, M. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res., 2015, 227(2-3), 278-282. [http://dx.doi.org/10.1016/j.psychres. 2015.02.021] [PMID: 25863824]
14. Goudie, A.J.; Cole, J.C. Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications. J. Psychopharmacol. (Oxford), 2008, 22(7), 815-817. [http://dx.doi.org/10.1177/0269881107082904] [PMID: 18753274]
15. Chouinard, G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr. Res., 1991, 5(1), 21-33. [http://dx.doi.org/10.1016/0920-9964(91)90050-2] [PMID: 1677263]
16. Remington, G.; Foussias, G.; Agid, O.; Fervaha, G.; Takeuchi, H.; Hahn, M. The neurobiology of relapse in schizophrenia. Schizophr. Res., 2014, 152(2-3), 381-390. [http://dx.doi.org/10.1016/j.schres. 2013.10.009] [PMID: 24206930]
17. Kirkpatrick, B.; Alphs, L.; Buchanan, R.W. The concept of supersensitivity psychosis. J. Nerv. Ment. Dis., 1992, 180(4), 265-270. [http://dx.doi.org/10.1097/00005053-199204000-00009] [PMID: 1348269]
18. Seeman, M.V.; Seeman, P. Is schizophrenia a dopamine supersensitivity psychotic reaction? Prog. Neuropsychopharmacol. Biol. Psychiatry, 2014, 48, 155-160. [http://dx.doi.org/10.1016/j.pnpbp.2013.10.003] [PMID: 24128684]
19. Takase, M.; Kanahara, N.; Oda, Y.; Kimura, H.; Watanabe, H.; Iyo, M. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. J. Psychopharmacol. (Oxford), 2015, 29(4), 383-389. [http://dx.doi.org/10.1177/0269881115570083] [PMID: 25735995]
20. Meyer, J.S.; Quenzer, L. Psychopharmacology: Drugs, the brain, and behavior, 2nd ed; Sinauer Associates: Sunderland, Mass, 2013.
21. Beaulieu, J.M.; Gainetdinov, R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev., 2011, 63(1), 182-217. [http://dx.doi.org/10.1124/pr.110.002642] [PMID: 21303898]
22. Seeman, P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses, 2010, 4(1), 56-73. [http://dx.doi.org/10.3371/CSRP.4.1.5] [PMID: 20643630]
23. Seeman, P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci. Ther., 2011, 17(2), 118-132. [http://dx.doi.org/10.1111/j.1755-5949.2010.00162.x] [PMID: 20560996]
24. Seeman, P.; Weinshenker, D.; Quirion, R.; Srivastava, L.K.; Bhardwaj, S.K.; Grandy, D.K.; Premont, R.T.; Sotnikova, T.D.; Boksa, P.; El-Ghundi, M.; Odowd, B.F.; George, S.R.; Perreault, M.L.; Männistö, P.T.; Robinson, S.; Palmiter, R.D.; Tallerico, T. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc. Natl. Acad. Sci. USA, 2005, 102(9), 3513-3518. [http://dx.doi.org/10.1073/pnas.0409766102] [PMID: 15716360]
25. Kostrzewa, R.M.; Kostrzewa, J.P.; Brown, R.W.; Nowak, P.; Brus, R. Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability. Neurotox. Res., 2008, 14(2-3), 121-128. [http://dx.doi.org/10.1007/BF03033804] [PMID: 19073420]
26. Dohlman, H.G.; Thorner, J. RGS proteins and signaling by heterotrimeric G proteins. J. Biol. Chem., 1997, 272(7), 3871-3874. [http://dx.doi.org/10.1074/jbc.272.7.3871] [PMID: 9064301]
27. Del'guidice, T.; Lemasson, M.; Beaulieu, J. Role of beta-arrestin 2 downstream of dopamine receptors in the basal ganglia. Front. Neuroanat., 2011, 5, 58. [http://dx.doi.org/10.3389/fnana.2011.00058]
28. Lefkowitz, R.J.; Shenoy, S.K. Transduction of receptor signals by β-arrestins. Science, 2005, 308(5721), 512-517. [http://dx.doi.org/10.1126/science.1109237] [PMID: 15845844]
29. Lieberman, J.A.; Kane, J.M.; Alvir, J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl.), 1987, 91(4), 415-433. [http://dx.doi.org/10.1007/BF00216006] [PMID: 2884687]
30. Erdely, H.A.; Tamminga, C.A.; Roberts, R.C.; Vogel, M.W. Regional alterations in RGS4 protein in schizophrenia. Synapse, 2006, 59(8), 472-479. [http://dx.doi.org/10.1002/syn.20265] [PMID: 16565965]
31. Rivero, G.; Gabilondo, A.M.; García-Sevilla, J.A.; Callado, L.F.; La Harpe, R.; Morentin, B.; Meana, J.J. Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment. Psychopharmacology (Berl.), 2013, 226(1), 177-188. [http://dx.doi.org/10.1007/s00213-012-2888-5] [PMID: 23093381]
32. Bychkov, E.R.; Ahmed, M.R.; Gurevich, V.V.; Benovic, J.L.; Gurevich, E.V. Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder. Neurobiol. Dis., 2011, 44(2), 248-258. [http://dx.doi.org/10.1016/j.nbd.2011.07.009] [PMID: 21784156]
33. Funk, A.J.; Haroutunian, V.; Meador-Woodruff, J.H.; McCullumsmith, R.E. Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia. Schizophr. Res., 2014, 159(1), 130-135. [http://dx.doi.org/10.1016/j.schres.2014.07.040] [PMID: 25153362]
34. Mackay, A.V.; Iversen, L.L.; Rossor, M.; Spokes, E.; Bird, E.; Arregui, A.; Creese, I.; Synder, S.H. Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psychiatry, 1982, 39(9), 991-997. [http://dx.doi.org/10.1001/archpsyc.1982.04290090001001] [PMID: 7115016]
35. Silvestri, S.; Seeman, M.V.; Negrete, J.C.; Houle, S.; Shammi, C.M.; Remington, G.J.; Kapur, S.; Zipursky, R.B.; Wilson, A.A.; Christensen, B.K.; Seeman, P. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl.), 2000, 152(2), 174-180. [http://dx.doi.org/10.1007/s002130000532] [PMID: 11057521]
36. Schwarz, J.; Antonini, A.; Tatsch, K.; Kirsch, C.M.; Oertel, W.H.; Leenders, K.L. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. Nucl. Med. Commun., 1994, 15(10), 806-813. [http://dx.doi.org/10.1097/00006231-199410000-00006] [PMID: 7838444]
37. Ginovart, N.; Wilson, A.A.; Hussey, D.; Houle, S.; Kapur, S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology, 2009, 34(3), 662-671. [http://dx.doi.org/10.1038/npp.2008.116] [PMID: 18688210]
38. Ruiz, J.; Gabilondo, A.M.; Meana, J.J.; García-Sevilla, J.A. Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims. Psychopharmacology (Berl.), 1992, 109(4), 410-414. [http://dx.doi.org/10.1007/BF02247716] [PMID: 1365855]
39. Seeman, P.; Guan, H.C.; Van Tol, H.H. Dopamine D4 receptors elevated in schizophrenia. Nature, 1993, 365(6445), 441-445. [http://dx.doi.org/10.1038/365441a0] [PMID: 8413587]
40. Ushijima, I.; Mizuki, Y.; Yamada, M. Development of tolerance and reverse tolerance to haloperidol-and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment. Pharmacol. Biochem. Behav., 1995, 50(2), 259-264. [http://dx.doi.org/10.1016/0091-3057(94)00309-7] [PMID: 7740066]
41. Ezrin-Waters, C.; Seeman, P. Tolerance of haloperidol catalepsy. Eur. J. Pharmacol., 1977, 41(3), 321-327. [http://dx.doi.org/10.1016/0014-2999(77)90325-9] [PMID: 556989]
42. Montanaro, N.; DallOlio, R.; Gandolfi, O.; Vaccheri, A. Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol. Eur. J. Pharmacol., 1982, 81(1), 1-9. [http://dx.doi.org/10.1016/0014-2999(82)90595-7] [PMID: 6889533]
43. Lane, R.F.; Blaha, C.D. Chronic haloperidol decreases dopamine release in striatum and nucleus accumbens in vivo: depolarization block as a possible mechanism of action. Brain Res. Bull., 1987, 18(1), 135-138. [http://dx.doi.org/10.1016/0361-9230(87)90042-6] [PMID: 3828839]
44. Halperin, R.; Guerin, J.J., Jr; Davis, K.L. Chronic administration of three neuroleptics: effects of behavioral supersensitivity mediated by two different brain regions in the rat. Life Sci., 1983, 33(6), 585-592. [http://dx.doi.org/10.1016/0024-3205(83)90134-0] [PMID: 6684202]
45. Chouinard, G.; Chouinard, V.A. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother. Psychosom., 2008, 77(2), 69-77. [http://dx.doi.org/10.1159/000112883] [PMID: 18230939]
46. Moncrieff, J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand., 2006, 114(1), 3-13. [http://dx.doi.org/10.1111/j.1600-0447.2006.00787.x] [PMID: 16774655]
47. van Harten, P.N.; Tenback, D.E. Tardive dyskinesia: clinical presentation and treatment. Int. Rev. Neurobiol., 2011, 98, 187-210. [http://dx.doi.org/10.1016/B978-0-12-381328-2.00008-0] [PMID: 21907088]
48. Emsley, R.; Oosthuizen, P.P.; Koen, L.; Niehaus, D.J.; Martinez, G. Symptom recurrence following intermittent treatment in firstepisode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J. Clin. Psychiatry, 2012, 73(4), e541-e547. [http://dx.doi.org/10.4088/JCP.11m07138] [PMID: 22579160]
49. Fallon, P.; Dursun, S.; Deakin, B. Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther. Adv. Psychopharmacol., 2012, 2(1), 13-22. [http://dx.doi.org/10.1177/2045125311431105] [PMID: 23983951]
50. De Hert, M.; Sermon, J.; Geerts, P.; Vansteelandt, K.; Peuskens, J.; Detraux, J. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: A systematic review and meta-analysis of randomized controlled trials with first-and second-generation antipsychotics. CNS Drugs, 2015, 29(8), 637-658. [http://dx.doi.org/10.1007/s40263-015-0269-4] [PMID: 26293744]
51. Llorca, P.M.; Vaiva, G.; Lancon, C. Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal. Can. J. Psychiatry, 2001, 46(1), 87-88. [PMID: 11221497]
52. Margolese, H.C.; Chouinard, G.; Beauclair, L.; Bélanger, M.C. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychopharmacol., 2002, 22(4), 347-352. [http://dx.doi.org/10.1097/00004714-200208000-00003] [PMID: 12172332]
53. Fatemi, S.H.; Reutiman, T.J.; Folsom, T.D.; Bell, C.; Nos, L.; Fried, P.; Pearce, D.A.; Singh, S.; Siderovski, D.P.; Willard, F.S.; Fukuda, M. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology, 2006, 31(9), 1888-1899. [http://dx.doi.org/10.1038/sj.npp.1301002] [PMID: 16407901]
54. Greengard, P.; Ballen, P.B.; Nairn, A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron, 1999, 23(3), 435-447. [http://dx.doi.org/10.1016/S0896-6273(00)80798-9]
55. Svenningsson, P.; Nishi, A.; Fisone, G.; Girault, J.A.; Nairn, A.C.; Greengard, P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 269-296. [http://dx.doi.org/10.1146/annurev.pharmtox.44.101802.121415] [PMID: 14744247]
56. Albert, K.A.; Hemmings, H.C., Jr; Adamo, A.I.; Potkin, S.G.; Akbarian, S.; Sandman, C.A.; Cotman, C.W.; Bunney, W.E., Jr; Greengard, P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch. Gen. Psychiatry, 2002, 59(8), 705-712. [http://dx.doi.org/10.1001/archpsyc.59.8.705] [PMID: 12150646]
57. Kunii, Y.; Hyde, T.M.; Ye, T.; Li, C.; Kolachana, B.; Dickinson, D.; Weinberger, D.R.; Kleinman, J.E.; Lipska, B.K. Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression. Mol. Psychiatry, 2014, 19(2), 192-199. [http://dx.doi.org/10.1038/mp.2012.174] [PMID: 23295814]
58. Pozzi, L.; Håkansson, K.; Usiello, A.; Borgkvist, A.; Lindskog, M.; Greengard, P.; Fisone, G. Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J. Neurochem., 2003, 86(2), 451-459. [http://dx.doi.org/10.1046/j.1471-4159.2003.01851.x] [PMID: 12871586]
59. Deslauriers, J.; Desmarais, C.; Sarret, P.; Grignon, S. Implication of the ERK/MAPK pathway in antipsychotics-induced dopamine D2 receptor upregulation and in the preventive effects of (±)-α-lipoic acid in SH-SY5Y neuroblastoma cells. J. Mol. Neurosci., 2014, 52(3), 378-383. [http://dx.doi.org/10.1007/s12031-013-0158-6] [PMID: 24203573]
60. Oda, Y.; Kanahara, N.; Kimura, H.; Watanabe, H.; Hashimoto, K.; Iyo, M. Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia. Neuropsychiatr. Dis. Treat., 2015, 11, 1845-1851. [http://dx.doi.org/10.2147/NDT.S86042] [PMID: 26251601]
61. Oda, Y.; Kanahara, N.; Iyo, M. Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: The pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia. Int. J. Mol. Sci., 2015, 16(12), 30144-30163. [http://dx.doi.org/10.3390/ijms161226228] [PMID: 26694375]
62. Farooq, S.; Agid, O.; Foussias, G.; Remington, G. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr. Bull., 2013, 39(6), 1169-1172. [http://dx.doi.org/10.1093/schbul/sbt137] [PMID: 24045038]
63. Caspi, A.; Davidson, M.; Tamminga, C.A. Treatment-refractory schizophrenia. Dialogues Clin. Neurosci., 2004, 6(1), 61-70. [PMID: 22034144]
64. Juarez-Reyes, M.G.; Shumway, M.; Battle, C.; Bacchetti, P.; Hansen, M.S.; Hargreaves, W.A. Clozapine eligibility: the effect of stringent criteria on ethnic, gender and age subgroups of schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1996, 20(8), 1341-1352. [http://dx.doi.org/10.1016/S0278-5846(96)00130-3] [PMID: 9004341]
65. McCutcheon, R.; Beck, K.; Bloomfield, M.A.; Marques, T.R.; Rogdaki, M.; Howes, O.D. Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J. Psychopharmacol. (Oxford), 2015, 29(8), 892-897. [http://dx.doi.org/10.1177/0269881115576688] [PMID: 25788157]
66. Yamanaka, H.; Kanahara, N.; Suzuki, T.; Takase, M.; Moriyama, T.; Watanabe, H.; Hirata, T.; Asano, M.; Iyo, M. Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis. Schizophr. Res., 2016, 170(2-3), 252-258. [http://dx.doi.org/10.1016/j.schres.2016.01.013] [PMID: 26775264]
67. Englisch, S.; Zink, M. Treatment-resistant schizophrenia: evidencebased strategies. Mens Sana Monogr., 2012, 10(1), 20-32. [http://dx.doi.org/10.4103/0973-1229.91588] [PMID: 22654380]
68. Leucht, S.; Tardy, M.; Komossa, K.; Heres, S.; Kissling, W.; Salanti, G.; Davis, J.M. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and metaanalysis. Lancet, 2012, 379(9831), 2063-2071. [http://dx.doi.org/10.1016/S0140-6736(12)60239-6] [PMID: 22560607]
69. Inoue, A.; Miki, S.; Seto, M.; Kikuchi, T.; Morita, S.; Ueda, H.; Misu, Y.; Nakata, Y. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not upregulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur. J. Pharmacol., 1997, 321(1), 105-111. [http://dx.doi.org/10.1016/S0014-2999(96)00920-X] [PMID: 9083792]
70. Lieberman, J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs, 2004, 18(4), 251-267. [http://dx.doi.org/10.2165/00023210-200418040-00005] [PMID: 15015905]
71. Zhou, L.W.; Qin, Z.H.; Weiss, B. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole. Neuropsychopharmacology, 1991, 4(1), 47-55. [PMID: 1672250]
72. Tadokoro, S.; Okamura, N.; Sekine, Y.; Kanahara, N.; Hashimoto, K.; Iyo, M. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr. Bull., 2012, 38(5), 1012-1020. [http://dx.doi.org/10.1093/schbul/sbr006] [PMID: 21402722]
73. Brust, T.F.; Hayes, M.P.; Roman, D.L.; Watts, V.J. New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling. Biochem. Pharmacol., 2015, 93(1), 85-91. [http://dx.doi.org/10.1016/j.bcp.2014.10.014] [PMID: 25449598]
74. Seeman, P. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole. Synapse, 2008, 62(12), 902-908. [http://dx.doi.org/10.1002/syn.20557] [PMID: 18792990]
75. Varela, F.A.; Der-Ghazarian, T.; Lee, R.J.; Charntikov, S.; Crawford, C.A.; McDougall, S.A. Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats. J. Psychopharmacol. (Oxford), 2014, 28(4), 376-386. [http://dx.doi.org/10.1177/0269881113504016] [PMID: 24045880]
76. Sillivan, S.E.; Konradi, C. Expression and function of dopamine receptors in the developing medial frontal cortex and striatum of the rat. Neuroscience, 2011, 199, 501-514. [http://dx.doi.org/10.1016/j.neuroscience.2011.10.004] [PMID: 22015925]
77. Kimura, H.; Kanahara, N.; Komatsu, N.; Ishige, M.; Muneoka, K.; Yoshimura, M.; Yamanaka, H.; Suzuki, T.; Komatsu, H.; Sasaki, T.; Hashimoto, T.; Hasegawa, T.; Shiina, A.; Ishikawa, M.; Sekine, Y.; Shiraishi, T.; Watanabe, H.; Shimizu, E.; Hashimoto, K.; Iyo, M. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr. Res., 2014, 155(1-3), 52-58. [http://dx.doi.org/10.1016/j.schres.2014.02.022] [PMID: 24667073]
78. Kane, J.M.; Peters-Strickland, T.; Baker, R.A.; Hertel, P.; Eramo, A.; Jin, N.; Perry, P.P.; Gara, M.; McQuade, R.D.; Carson, W.H.; Sanchez, R. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry, 2014, 75(11), 1254-1260. [http://dx.doi.org/10.4088/JCP.14m09168] [PMID: 25188501]
79. Kishi, T.; Matsuda, Y.; Matsunaga, S.; Iwata, N. Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr. Dis. Treat., 2015, 11, 419-434. [http://dx.doi.org/10.2147/NDT.S78977] [PMID: 25759585]
80. Azekawa, T.; Ohashi, S.; Itami, A. Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder. Neuropsychiatr. Dis. Treat., 2011, 7, 691-695. [http://dx.doi.org/10.2147/NDT.S26672] [PMID: 22128254]
81. Khanna, P.; Suo, T.; Komossa, K.; Ma, H.; Rummel-Kluge, C.; El-Sayeh, H.G.; Leucht, S.; Xia, J. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev., 2014, 1(1), CD006569. [http://dx.doi.org/10.1002/14651858.CD006569.pub5] [PMID: 24385408]
82. Adan-Manes, J.; Garcia-Parajua, P. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. J. Clin. Pharm. Ther., 2009, 34(2), 245-246. [http://dx.doi.org/10.1111/j.1365-2710.2008.00996.x] [PMID: 19250146]
83. Fagiolini, A.; Brugnoli, R.; Di Sciascio, G.; De Filippis, S.; Maina, G. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opin. Pharmacother., 2015, 16(5), 727-737. [http://dx.doi.org/10.1517/14656566.2015.1013029] [PMID: 25672664]
84. Ahmed, M.R.; Gurevich, V.V.; Dalby, K.N.; Benovic, J.L.; Gurevich, E.V. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J. Pharmacol. Exp. Ther., 2008, 325(1), 276-283. [http://dx.doi.org/10.1124/jpet.107.131987] [PMID: 18178904]
85. Deslauriers, J.; Desmarais, C.; Sarret, P.; Grignon, S. α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia. J. Mol. Neurosci., 2013, 50(1), 134-145. [http://dx.doi.org/10.1007/s12031-012-9884-4] [PMID: 22975849]